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Precis for use in the Table of Contents: In this randomized clinical trial of patients with 
cetuximab-refractory recurrent/metastatic HNSCC, cetuximab + temsirolimus induced durable 
responses in some patients (including 1 CR), indicating modest clinical activity. However, in an 
unselected population temsirolimus + cetuximab did not improve survival, though further 
investigation as a salvage option for patients with prior benefit from cetuximab monotherapy 
may be warranted. 
Keywords: Squamous Cell Carcinoma of Head and Neck  , cetuximab  , temsirolimus  , 
Neoplasm Metastasis  , Neoplasm Recurrence  , Local Genes  , erbB-1  , TOR Serine-Threonine 
Kinases
Abstract
Background:  Patients with cetuximab-resistant recurrent/metastatic head and neck squamous 
cell carcinoma (HNSCC) have poor outcomes. This study hypothesized that dual blockade of 
mTOR and EGFR would overcome cetuximab resistance based on the role of PI3K signaling in 
preclinical models of EGFR resistance.
Methods: In this multicenter randomized clinical study, patients with recurrent/metastatic 
HNSCC with documented progression on cetuximab (in any line in recurrent/metastatic setting) 
received temsirolimus 25 mg weekly + cetuximab (TC) 400/250mg/m2 weekly or single-agent 
temsirolimus (T). Primary outcome was progression free survival (PFS) of TC arm compared to 
T arm. Response rate, overall survival, toxicity were secondary outcomes.
Results: 80 patients were randomized to therapy with TC or T alone. There was no difference for 
the primary outcome of median PFS (TC arm: 3.5 months, T arm: 3.5 months). Response rate in 
the TC arm was 12.5% (5 responses, including 1 CR (2.5%)) compared to 2.5% in the T arm (1 
PR) (P=0.10). Responses were clinically meaningful in the TC arm (range: 3.6–9.1 months), but 
not in the T alone am (1.9 months). Fatigue, electrolyte abnormalities, and leukopenia were the 
most common grade 3+ adverse events and occurred in less than 20% of patients in both arms.  
Conclusion: The study did not meet its primary endpoint of improvement in PFS. However, 
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tolerability. The post-hoc observation of activity in patients with acquired resistance (after prior 
benefit from cetuximab monotherapy) may warrant further investigation.
Introduction
90% of head and neck squamous cell carcinomas (HNSCC) express epidermal growth 
factor receptor (EGFR) and its presence is associated with poor outcome[1]. Cetuximab, an IgG1 
monoclonal antibody that inhibits ligand binding to EGFR and stimulates antibody-dependent 
cell-mediated toxicity[2], has been demonstrated to improve overall survival, progression-free 
survival, and response rates in the recurrent or metastatic setting when added to standard 
chemotherapy1[3].  Single agent response rates of 9.7-13% have been noted in platinum-
refractory disease with single-agent cetuximab2[4], but patients eventually develop resistance and 
progress[5].
While resistance to cetuximab can occur through a variety of mechanisms, preclinical 
models suggest that downstream activation of the phosphoinositide 3-kinase (PI3K)/AKT 
pathway can play a key role in the development of cetuximab resistance[5]. AKT/mTOR 
activation is an early event in HNSCC carcinogenesis, and is implicated in progression from 
dysplasia to invasive carcinoma and predicts recurrence when identified at the surgical 
margin[6,7]. Independent activation of AKT predicts resistance to EGFR inhibitors in EGFR-
overexpressing cell lines[8]. Furthermore, it has been demonstrated that genetic alterations 
causing PI3K/AKT/mTOR activation, such as by expression of activated PIK3CA and RAS 
alleles, are sufficient to prevent a sustained response to cetuximab after an initial short-lasting 
beneficial effect[9].  
Consequently, it has been hypothesized that dual blockade of EGFR and mTOR may lead 
to improved efficacy in tumor inhibition. Temsirolimus, an ester of the immunosuppressive drug 
sirolimus, acts by binding to the intracellular cytoplasmic protein, FK506 binding protein 12 
(FKBP12), thereby inhibiting mammalian target of rapamycin (mTOR), a highly conserved 
serine-threonine kinase. In xenograft models, the combination of the EGFR small molecule 
tyrosine inhibitor erlotinib and temsirolimus was successful in demonstrating tumor 
inhibition[10]. However, a phase II trial evaluating the combination was halted early due to 
toxicity, notably head & neck edema, diarrhea, and asthenia[11]. A second phase II trial 
evaluating the combination of everolimus, a different mTOR inhibitor and derivative of 
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HNSCC showed a manageable toxicity profile but did not show significant benefit[12].  
Additional studies looked at combinations of mTOR inhibitors with chemotherapy or 
radiation[13-15]. 
The aim of this phase II randomized clinical trial was to evaluate progression-free 
survival with cetuximab + temsirolimus combination therapy compared to temsirolimus alone in 
patients with cetuximab-refractory metastatic or recurrent HNSCC. 
Materials and Methods
Study investigations were performed following approval by the local Institutional Review 
Board (Univ. of Chicago IRB#10-428-B, PI: Seiwert) and respective University of Chicago 
Phase 2 consortium member sites (full list is at www.clinicaltrials.gov, identifier: 
NCT01256385). Written informed consent was obtained from each patient. 
Patient Population
Patients were ≥18 years and required to have a histologic or cytologic diagnosis of 
HNSCC not amenable to curative intent therapy. Patients must have had progressive disease on a 
cetuximab-based therapy in the recurrent or metastatic setting. Acceptable prior cetuximab 
therapy was defined as palliative intent use either alone or in combination with chemotherapy for 
at least 2 weeks. Treatment with cetuximab during radiotherapy or chemotherapy was not 
sufficient. Patients were required to have Eastern Cooperative Group Performance Status 
(ECOG) 0-1, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 
v1.1), normal organ and marrow function, and a life expectancy of greater than 8 weeks. 
Pregnant women, patients with active brain metastases, and patients with uncontrolled 
intercurrent illness (including, but not limited to, symptomatic congestive heart failure, unstable 
angina pectoris, ongoing or active infection) were ineligible for the study. 
Investigational Treatment
A total of 80 patients were randomized to receive either temsirolimus + cetuximab (TC) 
or temsirolimus monotherapy (T). Randomization was 1:1 between the two arms using the 
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(oropharyngeal versus non-oropharyngeal origin). Randomization was done at the University of 
Chicago.
The initial cetuximab dose was a loading dose of 400 mg/m2 IV, and subsequent weekly 
doses were of 250 mg/m2 IV (given over 60 minutes). In both arms, temsirolimus was given at a 
dose of 25 mg weekly, infused IV over 30-60 minutes via infusion pump. Four weeks (28 days) 
constituted one cycle and treatment was continued until disease progression, intercurrent illness 
that prevented further administration of treatment, unacceptable adverse events, or the patient 
chose to withdraw from the study. At time of progression, patients treated on the T arm could 
cross over to the TC arm for a salvage therapy option. 
Restaging radiological evaluation was performed at baseline and then every 8 weeks. 
Disease progression (PD) was evaluated by the investigators using RECIST v1.1. Toxicity 
assessments according to National Cancer Institute Common Terminology Criteria for Adverse 
Events version 4.0 (NIH) were performed every two weeks for the first 8 weeks, and then 
monthly until the patient was taken off study.
Statistical Methods
The primary endpoint was progression-free survival (PFS), defined as time from 
randomization to disease progression or death from any cause.  It was assumed that temsirolimus 
as a single agent would not prolong PFS based on prior studies of ineffective targeted agents in 
HNSCC[16]. It was hypothesized that combination treatment would increase median PFS from 
2.0 months to 4.0 months, which corresponded to a hazard ratio of HR=2. A sample size of N=80 
patients (40 per arm) was chosen, to provide 90% power to detect such a difference based on a 
log rank test with a one-sided α=0.05 (assuming 24-month accrual and 6-month follow-up 
periods). 
Secondary endpoints were tumor response, OS, treatment related toxicity, and signal with 
TC combination therapy after PD on T monotherapy. PFS and OS were estimated by the Kaplan-
Meier method and compared between treatment arms using the log rank test[17]. Confidence 
intervals for median survival times were derived using the method of Broomeyer and 
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Patient characteristics and treatment administration
Patients were enrolled between February 2011 and May 2013 across 14 institutions. A 
total of 86 patients were randomized (43 per treatment arm, see Figure 1). Three patients in each 
arm did not start treatment and were considered non-evaluable and per the protocol not included 
in the analysis. The baseline characteristics for the 80 evaluable patients are listed in Table 1. 
The majority of patients were male (TC: 77.5%, T: 92.5%), with ages ranging from 39-86 years. 
Approximately 40% of tumors were located in the oropharynx and 60% at non-oropharynx sites.
Efficacy
PFS and OS are depicted in Figure 2. All 80 randomized patients were evaluable for PFS 
and OS. PFS was not significantly different between the two arms (logrank P=0.73). Median 
PFS time was 105 days for the TC arm (95% CI: 70-136 days) and 105 days for the T arm (95% 
CI: 77-147 days). OS was also not significantly improved with the combination therapy (logrank 
P=0.87). Median OS time was 177 days for the TC arm (95% CI: 146-247 days) and 176 days 
for the T arm (95% CI: 131-316 days).  
There was a trend toward a difference in response rates, with 5 patients (12.5%) having 
either a partial (N=4) or complete response (N=1) in the TC arm and only 1 patient (2.5%) 
having a partial response in the T arm (P=0.10) (Table 2). The duration of responses and prior 
history data are shown in Table 3.
Ten patients were taken off treatment due to an adverse event (6 in TC arm and 4 in T 
arm), 48 due to disease progression (26 in TC arm and 22 in T arm), 2 to pursue alternative 
treatments (1 in each arm), 6 withdrew (1 in TC arm and 5 in T arm), 6 discontinued for other 
reasons (2 in TC arm and 4 in T arm), and 8 patients died on therapy (4 in each arm).
Activity of combination therapy after failure of temsirolimus monotherapy
In total, 15 (37.5%) patients in T arm progressed and subsequently crossed over to 
receive the combination treatment. Of those 15, 5 were not evaluable due to coming off 
treatment prior to the first evaluation. Of the remaining 10 evaluable patients, 6 had a best 
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In both arms, all 80 patients were evaluable for toxicity. The most common any grade 
and 3+ grade AEs while patients were on their initially assigned treatment arm and deemed at 
least possibly related to study drug are listed in Table 4. The number of patients who 
experienced at least one grade 3+ AE was 28/40 (70%) in the TC arm, and 31/40 (77.5%) in the 
T arm. In both arms, the most common at least possibly related grade 3+ AEs were leukopenia, 
electrolyte abnormalities, and fatigue, with no grade 3+ AE occurring in more than 20% of 
patients in either arm. No grade 5 hematologic AEs were observed in either arm. Two grade 5 
non-hematologic adverse events were noted in the TC arm, one with pulmonary hemorrhage and 
one with death not otherwise specified. A clear cause of death could not be determined (in the 
presence of metastatic disease, no autopsy performed). Neither grade 5 AEs were thought to be 
related to the study drugs. There were no grade 5 non-hematologic adverse events in the T arm. 
Discussion
Cetuximab is an approved treatment for recurrent/metastatic HNSCC setting with modest 
response rates from 9.7%-13%, but patients eventually develop resistance[4,5]. Pre-clinical 
studies have demonstrated that upregulation of the PI3K/AKT/mTOR pathway is one mechanism 
by which cetuximab-resistance can develop[5]. Clinical studies of mTOR inhibition alone have 
shown poor activity in HNSCC[19]. In preclinical models blocking mTOR has been shown to 
reverse EGFR resistance, and has been proposed as a clinical candidate mechanism by several 
groups[9,10]. However prior phase II studies evaluating the tolerability and efficacy of dual 
inhibition of EGFR and mTOR in recurrent/metastatic, platinum-resistant HNSCC patients have 
either poor tolerability or, at tolerable doses, shown poor efficacy[11,12]. Poor tolerability in 
particular may be related to the use of small molecule EGFR inhibitor erlotinib, or continual 
mTOR inhibition with daily oral dosing of everolimus. Hence, in this study, we chose a different 
approach to accomplish EGFR and mTOR co-targeting, using the EGFR monoclonal antibody 
cetuximab, which, as commonly observed[20], may be easier to combine than a TKI. 
Additionally, we used temsirolimus given IV once weekly based on pharmacokinetic 
considerations with an intermittent weekly peak of mTOR inhibition[21]. Differences in 
tolerability between IV intermittent dosing and continual oral dosing are well described and may 















This article is protected by copyright. All rights reserved
This phase II randomized trial of cetuximab + temsirolimus versus temsirolimus alone in 
cetuximab-resistant, recurrent/metastatic HNSCC patients failed to meet its primary endpoint of 
demonstrating a difference in PFS. However, the combination was well-tolerated and the 
addition of temsirolimus to cetuximab in this cetuximab-resistant population induced responses 
in 12.5% (5/40) of patients, including 1 complete response, with duration of responses ranging 
from 3.6 months to 9.1 months (Table 3), which may support the preclinical evidence and 
mechanistic rationale for dual, vertical targeting of EGFR and PIK3K/mTOR pathways [9,10]. 
The long duration of response argues against re-sensitization which would result in more 
transient/shorter term responses from regrowth of resistant clones. Given that the temsirolimus-
alone comparator arm did not show meaningful activity neither response rate nor duration of 
response is likely driven by temsirolimus alone. Similarly, everolimus as a single agent also did 
not show activity[19]. Furthermore, some patients who progressed on temsiroliums and crossed 
over to the combination showed some disease stabilization, indicating that efficacy is due to the 
combination. 
Interestingly, responses occurred exclusively in non-oropharyngeal sites of origin, 
suggesting preferential activity in HPV-negative tumors. Activity of EGFR agents is primarily in 
HPV-negative tumors[23], and may relate to higher levels of EGFR expression in HPV-negative 
HNSCC[24]. 
Overall this is a negative study, and the median progression-free and overall survival do 
not support development in the overall population of EGFR-refractory HNSCC patients. 
Identification of a predictive biomarker to enrich a population with higher rate of benefit might 
support further development to provide a clinically meaningful treatment option for patients who 
fail prior cetuximab therapy. Biomarker development for cetuximab therapy in HNSCC to date 
has been unsuccessful, nevertheless more recent biomarker analyses with newer agents do 
suggest that HPV status and PTEN/PI3K influence upfront anti-EGFR therapy efficacy for 
HNSCC and should be explored further[23, 25].
This is a pre-immunotherapy patient cohort as is evident in the overall poor survival. 
However, after approval of anti-PD-1 agents in both the first and second line recurrent/metastatic 
setting, cetuximab and cetuximab combinations continue to play an important role in PD-L1 
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In conclusion the combination of temsirolimus and cetuximab shows modest clinical 
activity in cetuximab-refractory recurrent/metastatic HNSCC patients and meaningful duration 
of response, lending credence to the preclinical, mechanistic rationale for dual, vertical targeting 
of EGFR and PIK3K/mTOR pathways. However, overall this was a negative study, but further 
mechanistic and clinical investigation as a salvage treatment option in particular in patients with 
prior benefit from cetuximab monotherapy may be warranted.
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Figure 2. Kaplan-Meier curves for survival. (a) Progression-free survival. (b) Overall 
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Table 1: Baseline demographics and clinical characteristics.   







Sex     
   Male 31 (77.5) 37 (92.5) 
   Female 9 (22.5) 3 (7.5) 
Age, years     
   Median 60 61 
   Range 45-83 36-79 
Race     
   White 34 (85.0) 34 (85.0) 
   Black 5 (12.5) 3 (7.5) 
   Other 1 (2.5) 3 (7.5) 
Primary Site      
   Oropharynx 17 (42.5) 16 (40.0) 
   Non-oropharynx 23 (57.5) 24 (60.0) 
Time between 
cetuximab failure and 
trial onset (months) 
    
   Mean 2.7 1.0 




Table 2: Best response rates reported in both arms  
Best response 
Temsirolimus + Cetuximab Temsirolimus 
No. pts. % No. pts % 
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Partial Response 4 10.0 1 2.5 
Stable Response 21 52.5 20 50.0 
Progressive Disease 10 25.0 16 40.0 
Death < 1st Evaluation 3 7.5 1 2.5 
Off treatment for AEa < 1st 
evaluation 
1 2.5 1 2.5 
Not adequately assessed 0 0.0 1 2.5 
Overall Response Rate 5 12.5% 1 2.5% 
aAE, adverse event.  
 
 
Table 3. Characteristics of responses in patients with either a CRa or PRb  




Duration of best 




cetuximab failure and 
trial onset (months) 
Temsirolimus + Cetuximab  
CR non-oropharyngeal 9.1 PR, 15.4 1.6 
PR non-oropharyngeal 7.3 PR, 9.0 1.1 
PR non-oropharyngeal 5.7 SDc, 1.7 0.5 
PR non-oropharyngeal 4.2 PR, 9.2 2.8 
PR non-oropharyngeal 3.6 PR, 3.0 7.8 
Temsirolimus 
PR non-oropharyngeal 1.9 SD, 3.7 6.2 
aCR, complete response. bPR, partial response. cSD, stable disease. 
 
 
Table 4. Summary of most common adverse events at least possibly related in both 
treatment armsa  
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Grade  Any 3+ Any 3+ 
Hematologic AEsb         
Anemia 20 (50.0) 1 (2.5) 25 (62.5) 3 (7.5) 
Leukocytosis 0 (0.0) 0 (0.0) 2 (5.0) 2 (5.0) 
Lymphocyte count decreased 10 (25.0) 7 (17.5) 16 (40.0) 8 (20.0) 
Platelet count decreased 15 (37.5) 1 (2.5) 15 (37.5) 0 (0.0) 
White blood cell decreased 9 (22.5) 0 (0.0) 11 (27.5) 0 (0.0) 
Non-Hematologic AEs          
Alanine aminotransferase increased 11 (27.5) 2 (5.0) 8 (20.0) 0 (0.0) 
Alkaline phosphatase increased 10 (25.0) 0 (0.0) 7 (17.5) 0 (0.0) 
Anorexia 9 (22.5) 1 (2.5) 15 (37.5) 0 (0.0) 
Aspartate aminotransferase increased 8 (20.0) 0 (0.0) 6 (15.0) 0 (0.0) 
Cholesterol high 7 (17.5) 0 (0.0) 12 (30.0) 0 (0.0) 
Constipation 8 (20.0) 0 (0.0) 11 (27.5) 0 (0.0) 
Dry skin 13 (32.5) 0 (0.0) 5 (12.5) 0 (0.0) 
Dyspnea 3 (7.5) 1 (2.5) 8 (20.0) 1 (2.5) 
Edema face 7 (17.5) 1 (2.5) 4 (10.0) 0 (0.0) 
Fatigue 24 (60.0) 3 (7.5) 27 (67.5) 3 (7.5) 
Headache 4 (10.0) 2 (5.0) 4 (10.0) 1 (2.5) 
Hyperglycemia 16 (40.0) 3 (7.5) 22 (55.0) 5 (12.5) 
Hypertriglyceridemia 7 (17.5) 0 (0.0) 10 (25.0) 2 (5.0) 
Hypoalbuminemia 7 (17.5) 0 (0.0) 7 (17.5) 0 (0.0) 
Hypocalcemia 8 (20.0) 2 (5.0) 8 (20.0) 0 (0.0) 
Hypokalemia 12 (30.0) 2 (5.0) 8 (20.0) 0 (0.0) 
Hypomagnesemia 22 (55.0) 4 (10.0) 4 (10.0) 0 (0.0) 
Hypophosphatemia 10 (25.0) 6 (15.0) 9 (22.5) 1 (2.5) 
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Mucositis oral 16 (40.0) 3 (7.5) 14 (35.0) 1 (2.5) 
Nausea 13 (32.5) 0 (0.0) 13 (32.5) 0 (0.0) 
Rash acneiform 19 (47.5) 4 (10.0) 8 (20.0) 1 (2.5) 
Rash maculo-papular 5 (12.5) 0 (0.0) 7 (17.5) 0 (0.0) 
Vomiting 6 (15.0) 0 (0.0) 5 (12.5) 0 (0.0) 
Weight loss 6 (15.0) 0 (0.0) 8 (20.0) 0 (0.0) 
aFrequency cutoff for grade 1-2 AEs is 15%, and grade 3+ AEs is 5% for either arm. Maximum 
grade per patient reported.  
bAE, adverse event.  
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